Mutations in PIK3R1 Cause SHORT Syndrome

SHORT syndrome is a rare, multisystem disease characterized by short stature, anterior-chamber eye anomalies, characteristic facial features, lipodystrophy, hernias, hyperextensibility, and delayed dentition. As part of the FORGE (Finding of Rare Disease Genes) Canada Consortium, we studied individuals with clinical features of SHORT syndrome to identify the genetic etiology of this rare disease. Whole-exome sequencing in a family trio of an affected child and unaffected parents identified a de novo frameshift insertion, c.1906_1907insC (p.Asn636Thrfs∗18), in exon 14 of PIK3R1. Heterozygous mutations in exon 14 of PIK3R1 were subsequently identified by Sanger sequencing in three additional affected individuals and two affected family members. One of these mutations, c.1945C>T (p.Arg649Trp), was confirmed to be a de novo mutation in one affected individual and was also identified and shown to segregate with the phenotype in an unrelated family. The other mutation, a de novo truncating mutation (c.1971T>G [p.Tyr657∗]), was identified in another affected individual. PIK3R1 is involved in the phosphatidylinositol 3 kinase (PI3K) signaling cascade and, as such, plays an important role in cell growth, proliferation, and survival. Functional studies on lymphoblastoid cells with the PIK3R1 c.1906_1907insC mutation showed decreased phosphorylation of the downstream S6 target of the PI3K-AKT-mTOR pathway. Our findings show that PIK3R1 mutations are the major cause of SHORT syndrome and suggest that the molecular mechanism of disease might involve downregulation of the PI3K-AKT-mTOR pathway. SHORT syndrome is a rare, multisystem disease characterized by short stature, anterior-chamber eye anomalies, characteristic facial features, lipodystrophy, hernias, hyperextensibility, and delayed dentition. As part of the FORGE (Finding of Rare Disease Genes) Canada Consortium, we studied individuals with clinical features of SHORT syndrome to identify the genetic etiology of this rare disease. Whole-exome sequencing in a family trio of an affected child and unaffected parents identified a de novo frameshift insertion, c.1906_1907insC (p.Asn636Thrfs∗18), in exon 14 of PIK3R1. Heterozygous mutations in exon 14 of PIK3R1 were subsequently identified by Sanger sequencing in three additional affected individuals and two affected family members. One of these mutations, c.1945C>T (p.Arg649Trp), was confirmed to be a de novo mutation in one affected individual and was also identified and shown to segregate with the phenotype in an unrelated family. The other mutation, a de novo truncating mutation (c.1971T>G [p.Tyr657∗]), was identified in another affected individual. PIK3R1 is involved in the phosphatidylinositol 3 kinase (PI3K) signaling cascade and, as such, plays an important role in cell growth, proliferation, and survival. Functional studies on lymphoblastoid cells with the PIK3R1 c.1906_1907insC mutation showed decreased phosphorylation of the downstream S6 target of the PI3K-AKT-mTOR pathway. Our findings show that PIK3R1 mutations are the major cause of SHORT syndrome and suggest that the molecular mechanism of disease might involve downregulation of the PI3K-AKT-mTOR pathway. SHORT syndrome (MIM 269880) is a rare disorder characterized by short stature, hyperextensibility of joints and/or hernias, ocular depression, Rieger anomaly, and delays of tooth eruption.1Gorlin R.J. Cervenka J. Moller K. Horrobin M. Witkop Jr., C.J. Malformation syndromes. A selected miscellany.Birth Defects Orig. Artic. Ser. 1975; 11: 39-50PubMed Google Scholar Although these features provide the condition’s acronym, they do not capture the full range of clinical features, which can include a recognizable facial gestalt (triangular facies, lack of facial fat, and hypoplastic nasal alae with overhanging columella), a near universal partial lipodystrophy, insulin resistance, nephrophrocalcinosis, and hearing deficits, among many others.2Lipson A.H. Cowell C. Gorlin R.J. The SHORT syndrome: further delineation and natural history.J. Med. Genet. 1989; 26: 473-475Crossref PubMed Scopus (27) Google Scholar, 3Koenig R. Brendel L. Fuchs S. SHORT syndrome.Clin. Dysmorphol. 2003; 12: 45-49Crossref PubMed Scopus (25) Google Scholar, 4Aarskog D. Ose L. Pande H. Eide N. Autosomal dominant partial lipodystrophy associated with Rieger anomaly, short stature, and insulinopenic diabetes.Am. J. Med. Genet. 1983; 15: 29-38Crossref PubMed Scopus (48) Google Scholar, 5Reardon W. Temple I.K. Nephrocalcinosis and disordered calcium metabolism in two children with SHORT syndrome.Am. J. Med. Genet. A. 2008; 146A: 1296-1298Crossref PubMed Scopus (11) Google Scholar, 6Brodsky M.C. Whiteside-Michel J. Merin L.M. Rieger anomaly and congenital glaucoma in the SHORT syndrome.Arch. Ophthalmol. 1996; 114: 1146-1147Crossref PubMed Scopus (15) Google Scholar, 7Schwingshandl J. Mache C.J. Rath K. Borkenstein M.H. SHORT syndrome and insulin resistance.Am. J. Med. Genet. 1993; 47: 907-909Crossref PubMed Scopus (27) Google Scholar Notably, both developmental milestones and cognition are normal for individuals with SHORT syndrome.3Koenig R. Brendel L. Fuchs S. SHORT syndrome.Clin. Dysmorphol. 2003; 12: 45-49Crossref PubMed Scopus (25) Google Scholar The first description of SHORT syndrome was of a sibling pair whose parents displayed no obvious features.1Gorlin R.J. Cervenka J. Moller K. Horrobin M. Witkop Jr., C.J. Malformation syndromes. A selected miscellany.Birth Defects Orig. Artic. Ser. 1975; 11: 39-50PubMed Google Scholar This has been followed by several reports of sporadic occurrences, suggesting an autosomal-recessive or de novo dominant mode of inheritance.6Brodsky M.C. Whiteside-Michel J. Merin L.M. Rieger anomaly and congenital glaucoma in the SHORT syndrome.Arch. Ophthalmol. 1996; 114: 1146-1147Crossref PubMed Scopus (15) Google Scholar However, there have also been several reports of parent-child transmissions, including male-to-male transmission, consistent with an autosomal-dominant inheritance pattern for SHORT syndrome.3Koenig R. Brendel L. Fuchs S. SHORT syndrome.Clin. Dysmorphol. 2003; 12: 45-49Crossref PubMed Scopus (25) Google Scholar, 4Aarskog D. Ose L. Pande H. Eide N. Autosomal dominant partial lipodystrophy associated with Rieger anomaly, short stature, and insulinopenic diabetes.Am. J. Med. Genet. 1983; 15: 29-38Crossref PubMed Scopus (48) Google Scholar, 8Bankier A. Keith C.G. Temple I.K. Absent iris stroma, narrow body build and small facial bones: a new association or variant of SHORT syndrome?.Clin. Dysmorphol. 1995; 4: 304-312Crossref PubMed Scopus (15) Google Scholar, 9Sorge G. Ruggieri M. Polizzi A. Scuderi A. Di Pietro M. SHORT syndrome: a new case with probable autosomal dominant inheritance.Am. J. Med. Genet. 1996; 61: 178-181Crossref PubMed Scopus (54) Google Scholar The majority of affected individuals still appear to be simplex cases,3Koenig R. Brendel L. Fuchs S. SHORT syndrome.Clin. Dysmorphol. 2003; 12: 45-49Crossref PubMed Scopus (25) Google Scholar suggesting a significant contribution for de novo dominant mutations. Specific genes have been suggested to play a role in the etiology of SHORT syndrome. PITX2 (MIM 601542) was highlighted in an individual with Rieger anomaly and syndromic features including lipoatrophy, hyperextensibility, a ventricular septal heart defect, and dysmorphic facial features.10Karadeniz N.N. Kocak-Midillioglu I. Erdogan D. Bökesoy I. Is SHORT syndrome another phenotypic variation of PITX2?.Am. J. Med. Genet. A. 2004; 130A: 406-409Crossref PubMed Scopus (14) Google Scholar This individual had a familial chromosomal translocation involving PITX2.10Karadeniz N.N. Kocak-Midillioglu I. Erdogan D. Bökesoy I. Is SHORT syndrome another phenotypic variation of PITX2?.Am. J. Med. Genet. A. 2004; 130A: 406-409Crossref PubMed Scopus (14) Google Scholar Another individual with eye anomalies and short stature was found by microarray to have a large deletion spanning PITX2 and several other genes.11Lines M.A. Kozlowski K. Kulak S.C. Allingham R.R. Héon E. Ritch R. Levin A.V. Shields M.B. Damji K.F. Newlin A. Walter M.A. Characterization and prevalence of PITX2 microdeletions and mutations in Axenfeld-Rieger malformations.Invest. Ophthalmol. Vis. Sci. 2004; 45: 828-833Crossref PubMed Scopus (59) Google Scholar BMP4 (MIM 112262) is associated with microphthalmia and has been reported to be deleted, along with 14 other genes at 14q22.2, in a single individual diagnosed with SHORT syndrome.12Reis L.M. Tyler R.C. Schilter K.F. Abdul-Rahman O. Innis J.W. Kozel B.A. Schneider A.S. Bardakjian T.M. Lose E.J. Martin D.M. et al.BMP4 loss-of-function mutations in developmental eye disorders including SHORT syndrome.Hum. Genet. 2011; 130: 495-504Crossref PubMed Scopus (85) Google Scholar Although they appear to have a syndrome related to Axenfield-Rieger anomaly, affected individuals with PITX2 and BMP4 mutations10Karadeniz N.N. Kocak-Midillioglu I. Erdogan D. Bökesoy I. Is SHORT syndrome another phenotypic variation of PITX2?.Am. J. Med. Genet. A. 2004; 130A: 406-409Crossref PubMed Scopus (14) Google Scholar, 12Reis L.M. Tyler R.C. Schilter K.F. Abdul-Rahman O. Innis J.W. Kozel B.A. Schneider A.S. Bardakjian T.M. Lose E.J. Martin D.M. et al.BMP4 loss-of-function mutations in developmental eye disorders including SHORT syndrome.Hum. Genet. 2011; 130: 495-504Crossref PubMed Scopus (85) Google Scholar do not have the characteristic facial gestalt shared by the individuals in the original and subsequent descriptions of SHORT syndrome.1Gorlin R.J. Cervenka J. Moller K. Horrobin M. Witkop Jr., C.J. Malformation syndromes. A selected miscellany.Birth Defects Orig. Artic. Ser. 1975; 11: 39-50PubMed Google Scholar, 2Lipson A.H. Cowell C. Gorlin R.J. The SHORT syndrome: further delineation and natural history.J. Med. Genet. 1989; 26: 473-475Crossref PubMed Scopus (27) Google Scholar, 3Koenig R. Brendel L. Fuchs S. SHORT syndrome.Clin. Dysmorphol. 2003; 12: 45-49Crossref PubMed Scopus (25) Google Scholar, 4Aarskog D. Ose L. Pande H. Eide N. Autosomal dominant partial lipodystrophy associated with Rieger anomaly, short stature, and insulinopenic diabetes.Am. J. Med. Genet. 1983; 15: 29-38Crossref PubMed Scopus (48) Google Scholar, 6Brodsky M.C. Whiteside-Michel J. Merin L.M. Rieger anomaly and congenital glaucoma in the SHORT syndrome.Arch. Ophthalmol. 1996; 114: 1146-1147Crossref PubMed Scopus (15) Google Scholar, 7Schwingshandl J. Mache C.J. Rath K. Borkenstein M.H. SHORT syndrome and insulin resistance.Am. J. Med. Genet. 1993; 47: 907-909Crossref PubMed Scopus (27) Google Scholar, 13Haan E. Morris L. SHORT syndrome: distinctive radiographic features.Clin. Dysmorphol. 1998; 7: 103-107Crossref PubMed Scopus (6) Google Scholar The FORGE (Finding of Rare Disease Genes) Canada Consortium is a collaborative project with the goal of identifying genetic mutations for rare childhood diseases.14Majewski J. Schwartzentruber J.A. Caqueret A. Patry L. Marcadier J. Fryns J.P. Boycott K.M. Ste-Marie L.G. McKiernan F.E. Marik I. et al.FORGE Canada ConsortiumMutations in NOTCH2 in families with Hajdu-Cheney syndrome.Hum. Mutat. 2011; 32: 1114-1117Crossref PubMed Scopus (82) Google Scholar, 15Bernier F.P. Caluseriu O. Ng S. Schwartzentruber J. Buckingham K.J. Innes A.M. Jabs E.W. Innis J.W. Schuette J.L. Gorski J.L. et al.FORGE Canada ConsortiumHaploinsufficiency of SF3B4, a component of the pre-mRNA spliceosomal complex, causes Nager syndrome.Am. J. Hum. Genet. 2012; 90: 925-933Abstract Full Text Full Text PDF PubMed Scopus (132) Google Scholar, 16Hood R.L. Lines M.A. Nikkel S.M. Schwartzentruber J. Beaulieu C. Nowaczyk M.J. Allanson J. Kim C.A. Wieczorek D. Moilanen J.S. et al.FORGE Canada ConsortiumMutations in SRCAP, encoding SNF2-related CREBBP activator protein, cause Floating-Harbor syndrome.Am. J. Hum. Genet. 2012; 90: 308-313Abstract Full Text Full Text PDF PubMed Scopus (126) Google Scholar We ascertained individuals with SHORT syndrome by contacting the members of the FORGE Canada Consortium and selected international colleagues and asking whether the physicians were aware of any individual(s) diagnosed with SHORT syndrome. Affected individuals and family members were recruited from Medical Genetics Clinics in North America, Israel, and the United Kingdom. Approval of the study design was obtained from the institutional research ethics board at the Children’s Hospital of Eastern Ontario, and free and informed consent was obtained from each study subject (or parent, if appropriate) prior to enrollment. Each individual was assessed by a medical geneticist, ophthalmologist, and/or pediatrician. Affected individuals 2 and 5 were previously published as cases of SHORT syndrome with associated nephrocalcinosis.5Reardon W. Temple I.K. Nephrocalcinosis and disordered calcium metabolism in two children with SHORT syndrome.Am. J. Med. Genet. A. 2008; 146A: 1296-1298Crossref PubMed Scopus (11) Google Scholar The clinical description of the affected individuals is presented in Table 1. DNA was extracted according to standard protocols. Paternity was confirmed by the genotyping of nine polymorphic simple-tandem-repeat markers.Table 1Clinical Characteristics of Individuals with SHORT SyndromeAffected Individual 1Affected Individual 2Affected Individual 3Affected Individual 4Affected Individual 5Affected Individual 6Affected Individual 7Age at assessment2 years10 years10.4 yearsbirth to 18 years4 years32 yearsat birthGenderfemalemalemalemalemalefemalemalePIK3R1 mutationc.1906_1907insC-c.1971T>Gc.1945C>Tc.1945C>Tc.1945C>Tc.1945C>TGrowthBirth weight1.556 kg at 365Reardon W. Temple I.K. Nephrocalcinosis and disordered calcium metabolism in two children with SHORT syndrome.Am. J. Med. Genet. A. 2008; 146A: 1296-1298Crossref PubMed Scopus (11) Google Scholar weeks0.760 kg at 32 weeks2.22 kg at 40 weeks2.52 kg at 38 weeks2.27 kg at term2.55 kg at term2.18 kg at termHeight (percentile)76.5 cm (<3rd)120 cm (<3rd)126 cm (3rd)132.5 cm at 11 years (5th); 160 cm at 18 years (<3rd)122.3 cm at 11 years (<3rd)148.5 cm (<3rd)45 cmWeight (percentile)8 kg (<3rd)not reported21.8 kg (<3rd)23.5 kg at 11 years (<3rd); 43 kg at 18 years (<3rd)17.9 kg at 11 years (<3rd)44 kg (3rd)2.18 kgHead circumference (percentile)43 cm (<3rd)not reported51.5 cm (25th)45.5 cm at 20 months (3rd)49 cm (25th)49.5 cm (<3rd)34 cmBone agenormaldelayed by 2.5 yearsdelayed by 24 monthsdelayednot reportednot reportednot reportedConnective TissueHyperextensibilitynoyes; especially small jointsyes; especially small jointsnonone reportednoNAHerniasnoinguinal hernianononone reportednonoFaciesTriangular faciesyesyesyesyesyesyesyesOcular depressionyesyesyesyesyesyesyesAged appearanceyesyesyesyesyesto handsto handsDimpleyesnonoyesyesnonoHypoplastic ala anterior-chamber with hypoplastic on of iris on delays or of and of with with and or narrow narrow to reported in the W. Temple I.K. Nephrocalcinosis and disordered calcium metabolism in two children with SHORT syndrome.Am. J. Med. Genet. A. 2008; 146A: 1296-1298Crossref PubMed Scopus (11) Google W. Temple I.K. Nephrocalcinosis and disordered calcium metabolism in two children with SHORT syndrome.Am. J. Med. Genet. A. 2008; 146A: 1296-1298Crossref PubMed Scopus (11) Google A. Keith C.G. Temple I.K. Absent iris stroma, narrow body build and small facial bones: a new association or variant of SHORT syndrome?.Clin. Dysmorphol. 1995; 4: 304-312Crossref PubMed Scopus (15) Google A. Keith C.G. Temple I.K. Absent iris stroma, narrow body build and small facial bones: a new association or variant of SHORT syndrome?.Clin. Dysmorphol. 1995; 4: 304-312Crossref PubMed Scopus (15) Google are not septal and ventricular septal in a new The are not septal and ventricular septal We capture and sequencing of for affected individual and two unaffected parents and for affected individual 2 for the was with the of variant and were as for FORGE M. Schwartzentruber J.A. Patry L. S. G. E. et al.FORGE Canada ConsortiumMutations in cause syndrome in Med. Genet. 2012; PubMed Scopus Google Scholar with a on the and We and by the and a to that with both were subsequently were to with H. R. and short with PubMed Scopus Google Scholar and was with the A. M. E. A. K. A. K. D. S. M. M.A. The a for DNA sequencing PubMed Scopus Google Scholar were with and from downstream We assessed of by the which showed that had of by at 20 each and short and were with H. A. J. N. G. G. R. and PubMed Scopus Google Scholar with the and were that at of the variant We by both K. M. H. of genetic from sequencing PubMed Scopus Google Scholar and to identify whether they and whether they are in the the in the and 2012; or in previously at the and we the from affected individual and unaffected de novo were in the affected and they were found to be in both The in is to be a by The frameshift c.1906_1907insC in exon 14 of a in the encoding and is to of the by PIK3R1. genes with two obvious from each we assessed the sequencing of affected individual 2 for any rare in a were in PIK3R1 or for affected individual several were highlighted as rare and were confirmed by Sanger were found to be and were for SHORT syndrome in this affected individual. was for PIK3R1 and no of any PIK3R1 was by Sanger sequencing in affected individuals exon 14 of affected individual 3 was found to have a mutation (c.1971T>G in both and affected individual was found to have a mutation in both parents and to be by Affected individual W. Temple I.K. Nephrocalcinosis and disordered calcium metabolism in two children with SHORT syndrome.Am. J. Med. Genet. A. 2008; 146A: 1296-1298Crossref PubMed Scopus (11) Google Scholar as as affected and A. Keith C.G. Temple I.K. Absent iris stroma, narrow body build and small facial bones: a new association or variant of SHORT syndrome?.Clin. Dysmorphol. 1995; 4: 304-312Crossref PubMed Scopus (15) Google Scholar has been previously three affected individuals were found to have the mutation, c.1945C>T (p.Arg649Trp), as affected individual and this mutation the of a mutations are not in or the The of rare mutations in the exon of PIK3R1 in of affected the of the mutation in two affected and a consistent inheritance pattern in a family and de novo cases provide genetic that we have identified the molecular cause of SHORT syndrome. The of a mutation in a disorder as SHORT syndrome can be a the of affected individuals and clinical the clinical we not identify a PIK3R1 mutation in affected individual the affected individuals in study features of SHORT syndrome of the phenotype of affected individual 2 confirmed that several of the features of SHORT syndrome stature, hernias, delayed a lack of fat, and an anterior-chamber ocular Table However, facial features appear from of the individuals The facial features in the individuals include a alae and a that individual 2 not have SHORT syndrome the lack of a PIK3R1 mutation and the recognizable facial This that SHORT syndrome is a and that on the facial PIK3R1 the of the as as the and G. a family of Sci. Full Text PDF PubMed Scopus Google Scholar The two are in the and D. and in of Genet. 26: PubMed Scopus Google Scholar is and to kinase for to first 2 to be This can by to by to a or by phosphorylation the in insulin 7: PubMed Scopus Google Scholar are two in and the identified in the individuals with SHORT syndrome are in the This is also in the and A lymphoblastoid cell was to be from affected individual c.1906_1907insC for were not for affected individuals 3 or or for individuals from the family of individual showed that the of the were in in in from individuals with by mutations in and were and the findings were consistent with a truncating PIK3R1 mutation a identified a in of affected individual they were consistent in with the to of the in with the and we found that of and were in from the of affected individual in from of in the PI3K-AKT-mTOR from from Individuals with SHORT and full The in from the individual and two previously individuals with The two individuals mutations in encoding the of and encoding the of M. J.L. Kim S. A. E. K.J. A. et novo mutations in of the cause Genet. 2012; PubMed Scopus Google Scholar The the of a of the by as as by and by A was in from individual and and The a to in from individual of of S6 S6 which is by is a of of that to from individual S6 phosphorylation on and from an individual with a mutation and show S6 as previously M. J.L. Kim S. A. E. K.J. A. et novo mutations in of the cause Genet. 2012; PubMed Scopus Google Scholar are of signaling this in the of individual The in from the individual and two previously individuals with The two individuals mutations in encoding the of and encoding the of M. J.L. Kim S. A. E. K.J. A. et novo mutations in of the cause Genet. 2012; PubMed Scopus Google Scholar The the of a of the by as as by and by A was in from individual and and The a to in from individual of of S6 S6 which is by is a of of that to from individual S6 phosphorylation on and from an individual with a mutation and show S6 as previously M. J.L. Kim S. A. E. K.J. A. et novo mutations in of the cause Genet. 2012; PubMed Scopus Google Scholar are of signaling this in the of individual 1. Another that has been in is a the in an individual with and insulin C.A. G. R. M. H. S. J.P. of in insulin a variant with kinase PubMed Scopus Google Scholar, I. J. M. of 2008; PubMed Scopus Google Scholar there has been a of an individual with and a of and from a mutation in exon of A.M. A. E. A.M. and cells in a the of Med. 2012; PubMed Scopus Google Scholar However, and were still the mutation was of the and A.M. A. E. A.M. and cells in a the of Med. 2012; PubMed Scopus Google Scholar findings suggest phenotypic for mutations this mutations in PIK3R1 in the multisystem phenotype of SHORT syndrome Although insulin might be to be an of is not universal among individuals with SHORT syndrome and is not a of the affected individuals reported this might with with a deletion of show a in insulin and of S. H. K. A. K. K. et insulin and in the of Genet. PubMed Scopus Google Scholar was that the other by were in these and the in insulin S. H. K. A. K. K. et insulin and in the of Genet. PubMed Scopus Google Scholar of and also in and in suggesting that the is for normal D. and in of Genet. 26: PubMed Scopus Google Scholar of the phosphorylation of phosphatidylinositol and an important that the of important downstream including and as part of the a in to by to the and of at a Sci. 2012; PubMed Scopus Google Scholar of in the of the at a Sci. 2012; PubMed Scopus Google Scholar mutations in (MIM are in disorders as syndrome (MIM and syndrome (MIM which are characterized by and a to or mutations in of this have been in syndrome (MIM M. D. R.L. J. Schwartzentruber J.A. Nikkel S.M. et of Rare Disease Canada novo and mutations in and cause a of related Genet. 2012; PubMed Scopus Google Scholar (MIM M. D. R.L. J. Schwartzentruber J.A. Nikkel S.M. et of Rare Disease Canada novo and mutations in and cause a of related Genet. 2012; PubMed Scopus Google Scholar (MIM and M. J.L. Kim S. A. E. K.J. A. et novo mutations in of the cause Genet. 2012; PubMed Scopus Google Scholar, M. D. R.L. J. Schwartzentruber J.A. Nikkel S.M. et of Rare Disease Canada novo and mutations in and cause a of related Genet. 2012; PubMed Scopus Google Scholar the of a single with a truncating mutation in PIK3R1 that the mechanism SHORT syndrome in an to the that the phosphorylation of S6 to that there is of the signaling by the PI3K-AKT-mTOR as in as syndrome (MIM and of this are associated with cell and Although further of cell from other individuals with SHORT syndrome be for the of PIK3R1 mutations on the of the PI3K-AKT-mTOR of a single cell a we have shown that dominant mutations in PIK3R1 cause SHORT a recognizable syndrome. The findings also suggest that the molecular mechanism of the disease might involve downregulation of the PI3K-AKT-mTOR which is important for and is that of other members of this in The to the study and this not have been This was by the of Canada the of and the was by and is a whose is by the Medical and is by a and are the of a from the of This was selected for study by the FORGE Canada of J. J. M. M. and S. The for presented are as of in SHORT with to 3 et of phosphatidylinositol 3 kinase (PI3K) as proliferation, and survival. A component in this is the by PIK3R1. we identified a PIK3R1 mutation in two unrelated families affected by partial lipodystrophy, body short stature, and Rieger anomaly This mutation to and and insulin signaling in from affected and in PDF with et of stature, hyperextensibility of joints and/or ocular depression, Rieger anomaly, and syndrome is a developmental disorder with an genetic cause and that include insulin and lack of We ascertained two unrelated individuals with SHORT that the phenotype was to de novo mutations in the and sequencing in the two and unaffected PDF

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.